SIERRA ONCOLOGY, INC. (NASDAQ:SRRA) Files An 8-K Regulation FD Disclosure

SIERRA ONCOLOGY, INC. (NASDAQ:SRRA) Files An 8-K Regulation FD Disclosure

Story continues below


Regulation FD Disclosure.

Sierra Oncology, Inc.s updated corporation presentation is
attached hereto as Exhibit 99.1.

The information furnished with this report, including
Exhibit99.1, shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference into any other
filing under the Exchange Act or the Securities Act of 1933, as
amended, except as expressly set forth by specific reference in
such a filing.

Item9.01 Financial Statements and Exhibits.

Exhibit Number


99.1 Corporation Presentation



Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.

SIERRA ONCOLOGY, INC. (NASDAQ:SRRA) Recent Trading Information

SIERRA ONCOLOGY, INC. (NASDAQ:SRRA) closed its last trading session up +0.01 at 1.42 with 97,172 shares trading hands.

An ad to help with our costs